A preclinical study demonstrated that the combination of a CSF-1R inhibitor with PD-1 or CTLA4 antagonists elicited tumor regression, while the single use of PD-1 or CTLA4 inhibitors showed limited efficacy [16]. The gene discussed is CTLA4; the disease is neoplasm.